+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Atherosclerosis Drugs Market - Global Forecast 2026-2032- Product Image
Atherosclerosis Drugs Market - Global Forecast 2026-2032- Product Image
New

Atherosclerosis Drugs Market - Global Forecast 2026-2032

  • PDF Icon

    Report

  • 182 Pages
  • January 2026
  • Region: Global
  • 360iResearch™
  • ID: 5967871
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The atherosclerosis drugs market is experiencing significant transformation, driven by advancements in scientific research, novel treatment modalities, and evolving healthcare delivery systems. Senior decision-makers must stay ahead of these shifts, leveraging actionable intelligence to align strategies with changing therapeutic and commercial landscapes.

Market Snapshot: Atherosclerosis Drugs Market Growth and Outlook

The atherosclerosis drugs market expanded from USD 25.25 billion in 2025 to USD 26.76 billion in 2026 and is forecast to reach USD 37.57 billion by 2032, representing a robust CAGR of 5.84%. This upward trajectory highlights the sector’s rapid response to innovation, shifting payer requirements, and the increased prioritization of cardiovascular risk reduction within global public health agendas. Evolving payer methodologies and broadened therapy options contribute to a dynamic, highly competitive marketplace, making early strategy adaptation imperative for sustained growth.

Scope & Segmentation

This analysis delivers a comprehensive view into the key segments and regional factors shaping operational and strategic priorities in the atherosclerosis drugs market:

  • Therapeutic Classes: Statins; PCSK9 inhibitors; bile acid sequestrants; fibrates; niacin in both extended and immediate-release forms; omega-3 fatty acids; and adjunctive biologic therapies. Each class addresses diverse patient populations and therapeutic targets, aligning with evolving clinical guidelines and risk stratification practices.
  • Administration Routes: Oral, injectable, and intravenous formulations, providing tailored options for both chronic disease management and acute episodes, and optimizing adherence across care settings.
  • Distribution Channels: Hospital pharmacies, retail pharmacies, and online channels each influence market reach, patient access, supply chain structure, and workflow efficiency. These channels are essential to shaping distribution costs and support models.
  • Dosage Forms: Tablets, capsules, injectable biologics, and specialized delivery devices are incorporated based on clinical appropriateness, regional preferences, and supply consistency needs.
  • End-User Segments: Hospitals, outpatient clinics, and home care programs each pose unique educational, adherence, and reimbursement requirements, shaping provider engagement strategies and care delivery models.
  • Geographic Regions: Americas, Europe, Middle East & Africa, and Asia-Pacific regions drive distinct regulatory frameworks and payer approaches. These regions differ in health infrastructure, access levels, and adoption rates, impacting market entry and expansion tactics.
  • Technology Trends: Innovations in precision medicine, digital patient monitoring, molecular pathways, and resilient supply chains enable more targeted patient management and operational agility across variable healthcare systems.

Atherosclerosis Drugs Market: Key Takeaways

  • Rapid scientific advances are expanding treatment options, moving beyond traditional therapies toward biologics and RNA-based solutions that address complex patient risks.
  • Individualized risk stratification and precision therapeutics are becoming core focuses in clinical and payer strategies, supporting improved patient outcomes and better resource utilization.
  • Increasing reliance on integrated care models and value-based contracting links reimbursement to tangible clinical outcomes and the generation of strong post-marketing data.
  • Digital interventions and remote monitoring now play a central role in supporting treatment adherence, streamlining management, and facilitating ongoing patient engagement.
  • Pharmaceutical manufacturers are responding to market pressures by diversifying their sourcing, investing in regional hub development, and optimizing supply chains to mitigate disruptions and strengthen cost controls.
  • Commitment to equitable access and patient-centric engagement is growing, driving expanded outreach and educational initiatives in regions with limited healthcare resources.

Tariff Impact on Sourcing and Cost Management

Tariff measures implemented in the United States through 2025 have added complexity to atherosclerosis drug supply chains. Organizations are adapting procurement and sourcing strategies, increasing supplier diversification, and revising contract structures to control tariff-driven expenses. Emphasis is placed on efficiency improvements, proactive inventory management, and collaboration with payers and healthcare systems, ensuring pricing stability and the uninterrupted supply of active pharmaceutical ingredients and specialty components.

Methodology & Data Sources

This report utilizes a robust methodology, including interviews with clinicians, pharmacists, payers, and industry executives, combined with a thorough review of regulatory documents, clinical studies, and company records. Quantitative validation alongside scenario analysis and stakeholder feedback ensures that recommendations are both practical and aligned with real-world market dynamics.

Why This Report Matters

  • Empowers senior leadership to synchronize evidence-based decisions with specific market segments and emerging digital and therapeutic opportunities.
  • Provides clear guidance for building resilient supply chain structures, addressing regional market differences, and optimizing access solutions within diverse payer frameworks.
  • Facilitates informed investment and commercial strategy decisions in a complex, regulated, and highly segment-specific therapeutic environment.

Conclusion

Long-term success in the atherosclerosis drugs market relies on adaptable commercial strategies, multi-stakeholder collaboration, and targeted patient access initiatives. Proactive integration of data, operations, and policy will be essential to sustaining market leadership and improving health outcomes.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025
8. Atherosclerosis Drugs Market, by Drug Class
8.1. Bile Acid Sequestrants
8.1.1. Cholestyramine
8.1.2. Colesevelam
8.1.3. Colestipol
8.2. Fibrates
8.2.1. Fenofibrate
8.2.2. Gemfibrozil
8.3. Niacin
8.3.1. Extended Release
8.3.2. Immediate Release
8.4. Omega-3 Fatty Acids
8.4.1. Docosahexaenoic Acid
8.4.2. Eicosapentaenoic Acid
8.5. PCSK9 Inhibitors
8.5.1. Alirocumab
8.5.2. Evolocumab
8.6. Statins
8.6.1. Atorvastatin
8.6.2. Pravastatin
8.6.3. Rosuvastatin
8.6.4. Simvastatin
9. Atherosclerosis Drugs Market, by Administration Route
9.1. Injectable
9.2. Oral
9.2.1. Capsule
9.2.2. Tablet
10. Atherosclerosis Drugs Market, by Dosage Form
10.1. Capsule
10.2. Injection
10.3. Tablet
11. Atherosclerosis Drugs Market, by Distribution Channel
11.1. Hospital Pharmacy
11.2. Online Pharmacy
11.3. Retail Pharmacy
12. Atherosclerosis Drugs Market, by End User
12.1. Clinic
12.2. Home Care
12.3. Hospital
13. Atherosclerosis Drugs Market, by Region
13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific
14. Atherosclerosis Drugs Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Atherosclerosis Drugs Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. United States Atherosclerosis Drugs Market
17. China Atherosclerosis Drugs Market
18. Competitive Landscape
18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. Abbott Laboratories
18.6. Agepha Pharma US
18.7. Amgen Inc.
18.8. Anthos Therapeutics
18.9. Artery Therapeutics, Inc.
18.10. Astellas Pharma Inc.
18.11. AstraZeneca PLC
18.12. Bayer AG
18.13. Cardurion Pharmaceuticals
18.14. CSL Behring
18.15. Eli Lilly and Company
18.16. Esperion Therapeutics, Inc.
18.17. NewAmsterdam Pharma
18.18. Novartis AG
18.19. Novo Nordisk A/S
18.20. Pfizer Inc.
18.21. Regeneron Pharmaceuticals, Inc.
18.22. Sanofi SA
18.23. Takeda Pharmaceutical Company Limited
18.24. Verve Therapeutics
List of Figures
FIGURE 1. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
List of Tables
TABLE 1. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CHOLESTYRAMINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESEVELAM, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COLESTIPOL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FENOFIBRATE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GEMFIBROZIL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY REGION, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOCOSAHEXAENOIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EICOSAPENTAENOIC ACID, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ALIROCUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY EVOLOCUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ATORVASTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PRAVASTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ROSUVASTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SIMVASTATIN, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 99. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 100. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 101. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 102. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 103. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
TABLE 104. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 105. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 106. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 107. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
TABLE 108. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
TABLE 109. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
TABLE 111. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 112. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 113. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 114. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 115. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 116. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 117. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 118. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 119. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 120. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 121. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 122. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 123. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 124. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 125. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 126. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 127. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 128. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 129. AMERICAS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 130. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 131. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 132. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 133. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 134. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 135. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 136. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 137. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 138. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 139. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 140. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 141. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 142. NORTH AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 143. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 144. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 146. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 147. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 148. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 149. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 150. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 151. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 152. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 153. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 154. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 155. LATIN AMERICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 171. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 172. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 173. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 174. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 175. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 176. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 177. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 178. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 179. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 180. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 181. EUROPE ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 182. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 183. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 184. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 185. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 186. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 187. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 188. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 189. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 190. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 191. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 192. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 193. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 194. MIDDLE EAST ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 195. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 196. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 197. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 198. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 199. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 200. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 201. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 202. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 203. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 204. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 205. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 206. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 207. AFRICA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 208. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 209. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 210. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 211. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 212. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 213. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 214. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 215. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 216. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 217. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 218. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 219. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 220. ASIA-PACIFIC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 221. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 222. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 223. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 224. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 225. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 226. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 227. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 228. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 229. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 230. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 231. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 232. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 233. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 234. ASEAN ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 235. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 236. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 237. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 238. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 239. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 240. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 241. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 242. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 243. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 244. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 245. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 246. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 247. GCC ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 248. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 249. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 250. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 251. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 252. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 253. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 254. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 255. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 256. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 257. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 258. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 259. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 260. EUROPEAN UNION ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 261. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 262. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 263. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 264. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 265. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 266. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 267. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 268. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 269. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 270. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 271. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 272. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 273. BRICS ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 274. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 275. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 276. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 277. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 278. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 279. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 280. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 281. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 282. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 283. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 284. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 285. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 286. G7 ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 287. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 288. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 289. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 290. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 291. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 292. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 293. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 294. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 295. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 296. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 297. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 298. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 299. NATO ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 300. GLOBAL ATHEROSCLEROSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 301. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 302. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 303. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 304. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 305. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 306. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 307. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 308. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 309. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 310. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 311. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 312. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 313. UNITED STATES ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 314. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 315. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 316. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY BILE ACID SEQUESTRANTS, 2018-2032 (USD MILLION)
TABLE 317. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY FIBRATES, 2018-2032 (USD MILLION)
TABLE 318. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY NIACIN, 2018-2032 (USD MILLION)
TABLE 319. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY OMEGA-3 FATTY ACIDS, 2018-2032 (USD MILLION)
TABLE 320. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY PCSK9 INHIBITORS, 2018-2032 (USD MILLION)
TABLE 321. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY STATINS, 2018-2032 (USD MILLION)
TABLE 322. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
TABLE 323. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
TABLE 324. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
TABLE 325. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
TABLE 326. CHINA ATHEROSCLEROSIS DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Atherosclerosis Drugs market report include:
  • Abbott Laboratories
  • Agepha Pharma US
  • Amgen Inc.
  • Anthos Therapeutics
  • Artery Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Cardurion Pharmaceuticals
  • CSL Behring
  • Eli Lilly and Company
  • Esperion Therapeutics, Inc.
  • NewAmsterdam Pharma
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Verve Therapeutics

Table Information

Report AttributeDetails
No. of Pages182
PublishedJanuary 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 26.76 Billion
Forecasted Market Value ( USD ) by 2032 $ 37.57 Billion
Compound Annual Growth Rate5.8%
Regions CoveredGlobal
No. of Companies Mentioned21

Related Topics

Related Reports

Atherosclerosis Drugs Market Report 2025 - Product Image

Atherosclerosis Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Atherosclerosis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Atherosclerosis Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Atherosclerosis Drugs - Global Strategic Business Report - Product Image

Atherosclerosis Drugs - Global Strategic Business Report

  • Report
  • 389 Pages
  • Global
From
Atherosclerosis Therapeutics - Global Strategic Business Report - Product Image

Atherosclerosis Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035 - Product Image

Atherosclerosis Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.